The prevalence of hypertension in adult women is projected to rise from 48.6% in 2020 to 59.1% in 2050, alongside increases in diabetes and obesity.
The 2026 guideline introduces AHA/ACC Acute Pulmonary Embolism Clinical Categories to improve severity classification and evidence-based management of acute pulmonary embolism.
This guideline introduces AHA/ACC Acute Pulmonary Embolism Clinical Categories to improve severity classification and evidence-based management.
The Clinical Valve Coordinator is essential for improving access to care and patient outcomes in multidisciplinary teams managing valvular heart disease.
Based on your interests and feeds
Luteolin improved left ventricular ejection fraction (LVEF) and reduced inflammatory factors in atherosclerotic mice, indicating potential as a cardiovascular protective agent.
Anxiety and depression significantly reduced treatment effectiveness and increased major cardiovascular adverse events in ACS patients after PCI, compared to those without these conditions.
DurAVR significantly reduced indexed flow displacement from 4.0%/cm² to 3.5%/cm² and indexed flow reversal ratio from 3.9%/cm² to 2.6%/cm², restoring flow to control values.

“🔴 #EAPCI26 #EHJVSHD Simultaneous Publication 🔴 🫀 Biomimetic TAVR (#DurAVR) restores ascending aortic flow towards native physiology and is associated with 18% LV mass regression at 6 months (first-in-human CMR study) 👉 https://t.co/tV04Wc6RuA @EAPCIPresident https://t.co/LcH1cygHp7”
In patients with preexcited AF, intravenous amiodarone was associated with a VF risk of only 0.12% to 0.68%, suggesting it may be a safe alternative in resource-limited settings.
Patients with phonetically uncommon surnames experienced a 16.8-minute longer FMC-to-diagnosis time compared to those with common surnames (p=0.009).
A multifaceted intervention improved adherence to heart failure guidelines in primary care, achieving 61.8% adherence versus 28.7% in usual care (OR 6.27, p<0.01).
PCI before TAVR did not improve survival or reduce urgent revascularization but decreased nonurgent revascularization, with increased bleeding risk (OR 1.59).